SCHEMBL24317764

SCHEMBL24317764

CCOc1ccc(Cc2ccc3c4c(cccc24)N(Cc2ccc(OC)cc2)C3=O)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.51
CASP3 P42574 2/20 0.44
TDP1 Q9NUW8 1/20 0.41
CLTC Q00610 1/20 0.41
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41
CHRM5 P08912 2/20 0.41
MEN1 O00255 1/20 0.41
APAF1 O14727 1/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.41
UBE2N P61088 1/20 0.41
ATM Q13315 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CMA1 P23946 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22533375 0.89 MAPT (0.46) KDM4ETP53MAPTMEN1APAF1
SCHEMBL24317614 0.89 TDP1 (0.46) KDM4ECASP3TDP1CLTCTP53
SCHEMBL27006357 0.88 KDM4E (0.49) KDM4ECASP3TDP1CLTCCHRM5
SCHEMBL22532551 0.86 KDM4E (0.57) KDM4ECASP3TDP1CLTCMAPT
SCHEMBL24315767 0.85 KDM4E (0.57) KDM4ECASP3TDP1CLTCMAPT
SCHEMBL24315886 0.85 KDM4E (0.57) KDM4ECASP3TDP1CLTCMAPT
SCHEMBL24317582 0.82 LMNA (0.45) KDM4ETP53MAPTCHRM5MEN1
SCHEMBL22532792 0.81 KDM4E (0.60) KDM4ECASP3TDP1CLTCMAPT
SCHEMBL22533049 0.81 KDM4E (0.60) KDM4ECASP3TDP1CLTCCHRM5
SCHEMBL24317769 0.81 TDP1 (0.42) KDM4ETDP1CLTCMAPTCHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
WO-2022081927-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY NFATC1, CTSS, MMP12 KDM4E 791/4885CASP3 724/4885TDP1 383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.